ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Tevogen Bio Holdings Inc

Tevogen Bio Holdings Inc (TVGN)

1.85
-0.27
(-12.74%)
Closed April 21 4:00PM
1.90
0.05
(2.70%)
After Hours: 6:05PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.90
Bid
1.82
Ask
2.21
Volume
209,858
1.75 Day's Range 2.16
1.75 52 Week Range 21.09
Market Cap
Previous Close
2.12
Open
2.16
Last Trade
14
@
1.89
Last Trade Time
Financial Volume
$ 398,369
VWAP
1.8983
Average Volume (3m)
497,870
Shares Outstanding
165,421,084
Dividend Yield
-
PE Ratio
70.68
Earnings Per Share (EPS)
0.03
Revenue
-
Net Profit
4.41M

About Tevogen Bio Holdings Inc

Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

Sector
Blank Checks
Industry
Blank Checks
Headquarters
Wilmington, Delaware, USA
Founded
1970
Tevogen Bio Holdings Inc is listed in the Blank Checks sector of the NASDAQ with ticker TVGN. The last closing price for Tevogen Bio was $2.12. Over the last year, Tevogen Bio shares have traded in a share price range of $ 1.75 to $ 21.09.

Tevogen Bio currently has 165,421,084 shares outstanding. The market capitalization of Tevogen Bio is $310.99 million. Tevogen Bio has a price to earnings ratio (PE ratio) of 70.68.

TVGN Latest News

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities.Tevogen Bio plans to...

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of...

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf...

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment...

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services at Verita CSG, Inc., a...

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN) Chief Information Officer and Head of company’s Artificial Intelligence Initiative, Tevogen.ai, Mittul Mehta, has taken strides to emphasize the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.57-23.07692307692.472.531.751044862.35711638CS
4-2.62-57.96460176994.524.781.7511197013.31700937CS
12-2.2-53.65853658544.121.091.754978703.46699632CS
26-2.2-53.65853658544.121.091.754978703.46699632CS
52-2.2-53.65853658544.121.091.754978703.46699632CS
156-2.2-53.65853658544.121.091.754978703.46699632CS
260-2.2-53.65853658544.121.091.754978703.46699632CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

TVGN Discussion

View Posts
Monksdream Monksdream 1 week ago
TVGN SPAC junk new 52 lo

👍️0
2020trader 2020trader 2 weeks ago
TVGN down 12% today, expecting lower
👍️0
Monksdream Monksdream 2 weeks ago
SPAC junk
👍️0
2020trader 2020trader 2 weeks ago
down 17% today
👍️0
2020trader 2020trader 2 weeks ago
expecting lower
👍️0
Monksdream Monksdream 2 weeks ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 2 weeks ago
Will it grow legs after 9:30
https://ih.advfn.com/markets/nasdaq/premarket
👍️0
Monksdream Monksdream 2 weeks ago
Tevogen Bio Holdings Inc NASDAQ: TVGN

GoSymbol lookup
Health Care : Biotechnology | Company profile
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
👍️0

Your Recent History

Delayed Upgrade Clock